Agree Realty Corporation (ADC) News
Follow Agree Realty Corporation (ADC) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 19 public stories across 13 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Agree Realty Reports Q3 Results, Raises 2026 AFFO Guidance
Agree Realty reported Q3 2026 net income of $66.5 million, up 32.3%, and Core FFO of $143.4 million, up 17.2%. It raised 2026 AFFO per-share guidance to $4.58–$4.59.
EQUITY | Oct 20, 2026, 08:15 PM UTC
M
Agree Realty Reports Third-Quarter Revenue of $213.9M
EQUITY | Oct 20, 2026, 08:11 PM UTC
L
Agree Realty Reports Third-Quarter Net Income of $68.4 Million
EARNINGS | Oct 20, 2026, 08:05 PM UTC
M
Agree Realty Q3 Results Expected October 20
Agree Realty is scheduled to report Q3'26 results after the market closes on October 20. Revenue and EPS estimates were provided.
EQUITY | Oct 19, 2026, 11:00 AM UTC
M
Agree Realty Q3'26 Earnings Preview
Agree Realty is scheduled to report Q3'26 results on October 20 after the market closes.
EQUITY | Oct 13, 2026, 11:00 AM UTC
M
Agree Realty sets Q3 2026 earnings release and call
Agree Realty announced the date for its third-quarter 2026 earnings release and conference call.
EQUITY | Sep 30, 2026, 08:14 PM UTC
L
AstraZeneca to invest $2bn in Summit Therapeutics
Under the terms of the deal, AstraZeneca will buy newly-issued equity in the New York-listed oncology specialist, giving it rights equivalent to around 12% of Summit’s common stock, or around 10.6% on a fully diluted bas
EQUITY | Sep 29, 2026, 06:43 AM UTC
M
Agree Realty prices $400 million 5.650% notes due 2036
Agree Limited Partnership priced a $400 million public offering of 5.650% senior unsecured notes due 2036.
MNA | Sep 17, 2026, 08:05 PM UTC
L
Agree Realty declares $0.267 monthly dividend for common shares
Agree Realty’s board authorized and the company declared a monthly cash dividend of $0.267 per common share. The company also noted the monthly dividend’s annualized amount of $3.204 per common share, reflecting a 4…
EQUITY | Sep 10, 2026, 08:05 PM UTC
L
Agree Realty director bought $724,200 of common shares
Director John Rakolta Jr reported purchasing common shares on 2026-08-31. The weighted average price was $72.42 per share across multiple transactions for $724,200 total.
EQUITY | Sep 02, 2026, 08:12 PM UTC
L
Agree Realty Declares Monthly Dividends
Agree Realty declares monthly common and preferred dividends
EQUITY | Aug 11, 2026, 08:12 PM UTC
L
Multiple Stocks Near 50dma Support
Several stocks approach 50-day moving average support
EQUITY | Aug 03, 2026, 05:47 PM UTC
L
ADC - Agree Realty Corporation Reports Second Quarter 2026 Results
ADC - Agree Realty Corporation Reports Second Quarter 2026 Results
EARNINGS | Jul 30, 2026, 08:11 PM UTC
L
ADC Agree Realty RESULTS: Q2, Q2 Net Income $54.809M, Q2 core FFO per share $1.13, Q2 EPS $0.44, Q2 core FFO $136M
ADC Agree Realty RESULTS: Q2, Q2 Net Income $54.809M, Q2 core FFO per share $1.13, Q2 EPS $0.44, Q2 core FFO $136M
EARNINGS | Jul 30, 2026, 08:07 PM UTC
L
Agree Realty Raises FY2026 FFO Guidance from $4.54-$4.58 to $4.57-$4.59 vs $4.54 Est
Agree Realty (NYSE: ADC ) raises FY2026 FFO guidance from $4.54-$4.58 to $4.57-$4.59 vs $4.54 analyst estimate..
EARNINGS | Jul 30, 2026, 08:05 PM UTC
H
earnings calendar: • earnings before the open: abev adt aep ag agco agio algm alny amcx amrx aos apd apg avy bax bc bdc bdrbf bfly bgc bi bl
earnings calendar: • earnings before the open: abev adt aep ag agco agio algm alny amcx amrx aos apd apg avy bax bc bdc bdrbf bfly bgc bi bldr bmy bud ccc cfr chkp ci cmco cnk cnx crh crox crs csw cwt dar dfin dsx dtm ee
EARNINGS | Jul 30, 2026, 11:18 AM UTC
L
ADC Initiated Outperform W/$84.00 PT at Huntington
ADC Initiated Outperform W/$84.00 PT at Huntington
EQUITY | Jul 15, 2026, 11:47 AM UTC
L
Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform
Potential first-in-class N-myristoyltransferase inhibitor (NMTi) ADC payload with a differ
EQUITY | Jul 06, 2026, 05:06 AM UTC
L
InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in China
BEIJING, July 05, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a lea
GEOPOLITICS | Jul 06, 2026, 01:00 AM UTC